Our group develops research directed to the most prevalent health problems in thoracic pathologies. We are an associated group in IMIBIC composed by several emerging researcher who dedicate their principal work to clinical care in the Reina Sofia University Hospital (RSUH). The objectives of our researches are always oriented in achieving results that have applicability in clinical practice and influence the global management (diagnosis, therapy and monitoring) of the patient with thoracic pathology. We aim at establishing alliances with other groups nationwide and internationally, that carry out research based on omics of thoracic neoplasm and lung transplantation.
We want to consolidate our research in the Identification of early biomarkers in the development of Chronic Pulmonary Graft Dysfunction after lung transplantation, the value of lncRNA FENDRR and FOXF1as a prognostic factor for survival of lung adenocarcinoma, the impact of oxygenator of extracorporeal membrane on dysfunctional lung graft in a standardized porcine model of a lung transplant, the value of ex-vivo lung perfusion for optimizing suboptimal lung grafts, thus expanding the pool of valid lung transplant donors, and the study on the incidence of pulmonary thromboembolism in patients surgically intervened on by bronchogenic carcinoma.
Our group was a pioneer in demonstrating the usefulness of C1 inhibitor and Antithrombin III in the prevention of primary graft dysfunction after lung transplantation, which is the major cause of early mortality and morbidity after lung transplantation.
The incidence of graft dysfunction after lung transplantation remains high. Pulmonary graft failure is a form of acute respiratory distress (SDRA) or diffuse alveolar damage what happens in the first moments after the transplant. It is called primary graft failure (PGD) and it is the most frequent cause of death in the first 30 days post-transplant. The treatment of PDG is, essentially, support. The objective of the project is to analyze the results obtained with the use of ECMO as intraoperative support during lung transplantation in a porcine model, and extending its use to immediate post-transplant, compared to transplants performed without ECMO support. In parallel, it is intended to perform a study of both inflammatory markers and the hypoxia pathway in both study groups. With this, you can obtain objective results that allow correlate the function of the pulmonary graft with the clinical-pathological determinations and, in last term, being able to detect the subgroup of transplants that would most benefit from intraoperative cardiorespiratory support with ECMO.
The recent introduction of ex vivo lung perfusion (EVLP) as a technique to assess and recondition lungs from marginal donors represents a new era in the field of lung transplantation. Not only has EVLP enabled an expansion in the availability of transplantable organs; it has also deeply challenged the concept of lung suitability itself. In fact, organs previously not considered for transplantation are now safely used with outcomes like those of standard donor lungs. We intend to demonstrate the value of EVLP for optimizing suboptimal lung grafts, thus expanding our pool of valid lung transplant donors.
SEPAR - Sociedad española de neumología y cirugía torácica
NEUMOSUR - Asociación de neumología y cirugía torácica del sur
SECT - Sociedad española de cirugía torácica
- Lung preservation
- chronic rejection
- bronchiolitis obliterans. Endothelium
- oxidative stress
- lung cancer
- ex-vivo lung perfusion